Fatima, T., Rayees, T.K.M., Shoaib, M.A.N., Khaleq, M.A., Fatima, A.
In the prophylaxis of stroke in Non valvular Atrial Fibrillation (NVAF) as well as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) treatment, the Novel Oral Anticoagulants are becoming popular management option. These NOACs have efficacy similar to that of Warfarin along with non inferior safety profiles. Though Warfarin has been widely used because of its anticoagulant effect and also has a probable reversibility in terms of bleeding, it may also be disadvantageous sometimes in few cases such as food interactions, drug and drug interaction, having a poor and unpredictable therapeutic response. The use of Novel Oral Anticoagulants (NOACs), approved by U.S Food and Drug Administration (FDA) rendered a new hope in patients who needed anticoagulant therapy. There are about four Novel Oral Anticoagulants approved by FDA, which includes Dabigatran (direct thrombin inhibitor), Rivaroxaban, Apixaban and Edoxaban (selective factor Xa Inhibitors). The predictable pharmacokinetics and minimal drug interactions of apixaban should allow for safe anticoagulation in the majority of patients, including temporary interruption for elective procedures. The main aim is to provide better treatment and prophylaxis of stroke, venous thromboembolism and Pulmonary Embolism using Novel Oral Anticoagulants (NOACs) as they exhibit minimal adverse effects when compared to Warfarin.
Stroke, Non valvular Atrial Fibrillation (NVAF), Deep Vein Thrombosis (DVT), Warfarin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban
Cite This Article
Fatima, T., Rayees, T.K.M., Shoaib, M.A.N., Khaleq, M.A., Fatima, A. (2016). Prophylaxis of Stroke and a Therapeutic Approach to Venous Thromboembolism Using Novel Oral Anticoagulants (NOAC’s), International Journal for Pharmaceutical Research Scholars (IJPRS), 5(3), 120-127.